74 results on '"West, Michael L."'
Search Results
2. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
3. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
4. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
5. Lentivirus-mediated gene therapy for Fabry disease
6. Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy.
7. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
8. How well does urinary lyso-Gb 3 function as a biomarker in Fabry disease?
9. Gender-specific plasma proteomic biomarkers in patients with Anderson–Fabry disease
10. Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease.
11. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.
12. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
13. Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report.
14. NMR solution structure of the RNA-binding peptide from human immunodeficiency virus (type 1) Rev
15. Targeting HIV-1 protease: a test of drug-design methodologies
16. Patients with Fabry disease on dialysis in the United States
17. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years.
18. Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report.
19. Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis.
20. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
21. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
22. Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.
23. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
24. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.
25. Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry.
26. Total synthesis of (pm)-calanolide A, a non-nucleoside inhibitor of HIV-1 reverse transcriptase
27. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease
28. A modification of the urine osmolal gap: an improved method for estimating urine ammonium.
29. A renal mechanism limiting the degree of potassium loss in severely hyperglycemic patients.
30. Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes.
31. Possible Role of the Intestinal P‐450 Enzyme System in a Cyclosporine‐Clarithromycin Interaction.
32. Valvular heart disease complicating advanced Fabry disease: Association with chronic kidney disease.
33. Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype.
34. Lyso Gb3 and Gb3 analogues in Fabry disease patients with A143P genotype: A cross-sectional analysis by the CFDR study group.
35. Total synthesis of (+-)-calanolide A, a non-nucleoside inhibitor of HIV-1 reverse transcriptase.
36. The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD).
37. Dde as a Protecting Group for Carbohydrate Synthesis.
38. Solid-Phase Oligosaccharide Chemistry and Its Application to Library Synthesis.
39. BRONCHIOLITIS OBLITERANS AND ORGANIZING PNEUMONIA IN RENAL TRANSPLANT RECIPIENTS.
40. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing.
41. Retrospective review of recent ASA prescribing practices for primary prevention of major adverse cardiovascular events in the Canadian Fabry Disease Initiative cohort.
42. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy.
43. Determination of the crystal structure and substrate specificity of ananain.
44. Corrigendum to "Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing" [2021 Sep-Oct;134(1–2):117–131].
45. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis.
46. Clinical characteristics of female patients enrolled in the FollowME Fabry Pathfinders registry.
47. FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years.
48. Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey.
49. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis.
50. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.